Statin therapy reduces serum levels of glycosylphosphatidylinositol-specific phospholipase D
Statin therapy reduces serum levels of glycosylphosphatidylinositol-specific phospholipase D
复制标题
DOI：
10.1016/j.trsl.2007.03.008
复制
发表时间：
2007-09-01
影响因子：
7.8
通讯作者：
Williams, Craig D.
中科院分区：
文献类型：
--
作者：
Deeg, Mark A.;Raikwar, Nandita S.;Williams, Craig D.
他汀类药物治疗与低密度、极低密度和高密度脂蛋白代谢的改变有关。他汀类药物对含有糖基磷脂酰肌醇特异性磷脂酶D的少量高密度脂蛋白颗粒的影响尚未得到检验。糖基磷脂酰肌醇特异性磷脂酶D(GPI-PLD)与甘油三酯代谢密切相关。采用双盲交叉设计，比较辛伐他汀(80 Mg)和阿托伐他汀(80 Mg)对13例低高密度脂蛋白患者的血脂和糖基磷脂酰肌醇特异性磷脂酶D水平的影响。两种他汀类药物均可降低胆固醇、甘油三酯和载脂蛋白B，并显著降低血清糖基磷脂酰肌醇特异性磷脂酶D水平(16%)。这种他汀类作用似乎发生在质室，因为他汀类药物都没有改变HepG2细胞中GPI-PLD的mRNA水平。血清糖基磷脂酰肌醇特异性磷脂酶D水平受他汀类药物的调节，可能代表了影响血清甘油三酯水平的另一种生化机制。
Statin therapy is associated with changes in low-density, very low-density, and high-density lipoprotein metabolism. The effect of statin therapy on a minor high-density lipoprotein particle containing glycosylphosphatidylinositol-specific phospholipase D has not been examined. Glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD) has been implicated in triglyceride metabolism. A double-blind, crossover design comparing the effect of simvastatin (80 mg) and atorvastatin (80 mg) on serum lipid and glycosylphosphatidylinositol-specific phospholipase D levels was conducted in 13 patients with low high-density lipoproteins. Both statins reduced cholesterol, triglycerides, and apolipoprotein B and significantly lowered serum glycosylphosphatidylinositol-specific phospholipase D levels (16%). This statin effect seems to occur in the plasma compartment as neither statin altered GPI-PLD mRNA levels in HepG2 cells. Serum glycosylphosphatidylinositol-specific phospholipase D levels are regulated by statins and may represent an additional biochemical mechanism for affecting serum triglyceride levels.